NYSE: IQV |
| Healthcare / Medical Diagnostics & Research / USA |
207.73 | +4.39 | +2.16% | Vol 783.84K | 1Y Perf -15.13% |
May 26th, 2022 16:04 DELAYED |
BID | 169.98 | ASK | 245.00 | ||
Open | 203.64 | Previous Close | 207.73 | ||
Pre-Market | - | After-Market | 207.73 | ||
- - | - -% |
Target Price | 275.08 | Analyst Rating | Strong Buy 1.19 | |
Potential % | 32.42 | Finscreener Ranking | ★+ 42.51 | |
Insiders Trans % 3/6/12 mo. | -/-/-33 | Value Ranking | + 34.73 | |
Insiders Value % 3/6/12 mo. | -/-96/-96 | Growth Ranking | ★★★ 52.36 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-96/-96 | Income Ranking | — - | |
Price Range Ratio 52W % | 13.51 | Earnings Rating | Neutral | |
Market Cap | 39.32B | Earnings Date | 27th Apr 2022 | |
Alpha | 0.00 | Standard Deviation | 0.09 | |
Beta | 1.41 |
Today's Price Range 203.64208.68 | 52W Range 195.57285.61 | 5 Year PE Ratio Range 16.00199.70 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 2.92% | ||
1 Month | -1.19% | ||
3 Months | -11.22% | ||
6 Months | -20.73% | ||
1 Year | -15.13% | ||
3 Years | 52.32% | ||
5 Years | 141.49% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 4.23 | |||
ROE last 12 Months | 18.70 | |||
ROA (5Y Avg) | 1.15 | |||
ROA last 12 Months | 4.49 | |||
ROC (5Y Avg) | 4.06 | |||
ROC last 12 Months | 7.39 | |||
Return on invested Capital Q | 2.11 | |||
Return on invested Capital Y | 2.13 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 5.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
36.40 | ||||
6.45 | ||||
2.74 | ||||
15.20 | ||||
1.06K | ||||
13.27 | ||||
-3.05 | ||||
31.27 | ||||
49.66B | ||||
Forward PE | 18.76 | |||
PEG | 2.46 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.80 | ||||
0.90 | ||||
0.68 | ||||
2.19 | ||||
4.50 | ||||
Leverage Ratio | 4.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
34.00 | ||||
11.60 | ||||
20.20 | ||||
4.70 | ||||
7.71 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
14.03B | ||||
74.14 | ||||
8.82 | ||||
9.85 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 2.27 | 2.34 | 3.08 |
Q04 2021 | 2.25 | 2.42 | 7.56 |
Q03 2021 | 1.99 | 2.02 | 1.51 |
Q02 2021 | 1.92 | 1.94 | 1.04 |
Q01 2021 | 1.70 | 2.05 | 20.59 |
Q04 2020 | 1.80 | 2.00 | 11.11 |
Q03 2020 | 1.41 | 1.50 | 6.38 |
Q02 2020 | 0.91 | 1.03 | 13.19 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 2.23 | -1.76 | Negative |
9/2022 QR | 2.32 | 0.87 | Positive |
12/2022 FY | 9.49 | 0.42 | Positive |
12/2023 FY | 10.84 | 0.56 | Positive |
Next Report Date | - |
Estimated EPS Next Report | 2.27 |
Estimates Count | 6 |
EPS Growth Next 5 Years % | 14.80 |
Volume Overview | |
---|---|
Volume | 783.84K |
Shares Outstanding | 189.28K |
Shares Float | 166.97M |
Trades Count | 17.75K |
Dollar Volume | 162.08M |
Avg. Volume | 1.08M |
Avg. Weekly Volume | 907.43K |
Avg. Monthly Volume | 1.21M |
Avg. Quarterly Volume | 1.11M |
IQVIA Holdings Inc. (NYSE: IQV) stock closed at 207.73 per share at the end of the most recent trading day (a 2.16% change compared to the prior day closing price) with a volume of 783.84K shares and market capitalization of 39.32B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 77000 people. IQVIA Holdings Inc. CEO is Ari Bousbib.
The one-year performance of IQVIA Holdings Inc. stock is -15.13%, while year-to-date (YTD) performance is -26.37%. IQV stock has a five-year performance of 141.49%. Its 52-week range is between 195.57 and 285.61, which gives IQV stock a 52-week price range ratio of 13.51%
IQVIA Holdings Inc. currently has a PE ratio of 36.40, a price-to-book (PB) ratio of 6.45, a price-to-sale (PS) ratio of 2.74, a price to cashflow ratio of 15.20, a PEG ratio of 2.32, a ROA of 4.49%, a ROC of 7.39% and a ROE of 18.70%. The company’s profit margin is 7.71%, its EBITDA margin is 20.20%, and its revenue ttm is $14.03 Billion , which makes it $74.14 revenue per share.
Of the last four earnings reports from IQVIA Holdings Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.27 for the next earnings report. IQVIA Holdings Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for IQVIA Holdings Inc. is Strong Buy (1.19), with a target price of $275.08, which is +32.42% compared to the current price. The earnings rating for IQVIA Holdings Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IQVIA Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IQVIA Holdings Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 7.50, CCI20 : -12.82, Chaikin Money Flow : -0.06, MACD : -5.53, Money Flow Index : 47.25, ROC : 2.22, RSI : 46.48, STOCH (14,3) : 73.83, STOCH RSI : 1.00, UO : 51.71, Williams %R : -26.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IQVIA Holdings Inc. in the last 12-months were: John G. Danhakl (Buy at a value of $2 729 300), John P. Connaughton (Sold 555 094 shares of value $145 767 680 ), Kevin C. Knightly (Sold 6 055 shares of value $1 513 750 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
CEO: Ari Bousbib
Telephone: +1 919 998-2000
Address: 4820 Emperor Boulevard, Durham 27703, NC, US
Number of employees: 77 000
Fri, 29 Apr 2022 07:56 GMT IQVIA Holdings (IQV) Gets a Buy Rating from Deutsche Bank
- TipRanks. All rights reserved.Tue, 12 Apr 2022 12:56 GMT IQVIA Holdings (IQV) Receives a Buy from Mizuho Securities
- TipRanks. All rights reserved.Tue, 12 Apr 2022 03:35 GMT IQVIA Holdings (IQV) Receives a Buy from Deutsche Bank
- TipRanks. All rights reserved.Wed, 16 Feb 2022 16:43 GMT IQVIA Holdings (IQV) Received its Third Buy in a Row
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.